Azapropazone

Identification

Name
Azapropazone
Accession Number
DB07402
Type
Small Molecule
Groups
Withdrawn
Description
Not Available
Structure
Thumb
Synonyms
  • Azapropazone
International/Other Brands
Rheumox (Amdipharm Mercury Company Limited)
Categories
UNII
K2VOT966ZI
CAS number
13539-59-8
Weight
Average: 298.3397
Monoisotopic: 298.14297584
Chemical Formula
C16H18N4O2
InChI Key
WOIIIUDZSOLAIW-NSHDSACASA-N
InChI
InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
IUPAC Name
(4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
SMILES
[H][[email protected]@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 5-androstenedione.Experimental, Illicit
AbciximabAzapropazone may increase the anticoagulant activities of Abciximab.Approved
AcebutololAzapropazone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Acemetacin.Approved
AcenocoumarolAzapropazone may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azapropazone.Approved, Vet Approved
AclarubicinAzapropazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.Approved
AliskirenAzapropazone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alminoprofen.Experimental
AlprenololAzapropazone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azapropazone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide.Approved
AmikacinAzapropazone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAzapropazone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinAzapropazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAzapropazone may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Azapropazone.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Azapropazone is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anisodamine.Investigational
annamycinAzapropazone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.Approved
Antithrombin III humanAzapropazone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanAzapropazone may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Azapropazone is combined with Apocynin.Investigational
ApramycinAzapropazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Azapropazone.Approved, Investigational
ArbekacinAzapropazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAzapropazone may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAzapropazone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAzapropazone may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Atamestane.Investigational
AtenololAzapropazone may decrease the antihypertensive activities of Atenolol.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.Approved
BalsalazideAzapropazone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAzapropazone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAzapropazone may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAzapropazone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.Approved
BenorilateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone.Approved, Vet Approved
BetaxololAzapropazone may decrease the antihypertensive activities of Betaxolol.Approved
BevantololAzapropazone may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone.Approved, Investigational
BisoprololAzapropazone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAzapropazone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAzapropazone may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bucillamine.Investigational
BucindololAzapropazone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bufexamac.Experimental
BufuralolAzapropazone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bumadizone.Experimental
BumetanideAzapropazone may decrease the diuretic activities of Bumetanide.Approved
BupranololAzapropazone may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Azapropazone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.Approved, Vet Approved, Withdrawn
CarteololAzapropazone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAzapropazone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azapropazone.Approved, Investigational
CeliprololAzapropazone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAzapropazone may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Azapropazone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.Approved
CinoxacinAzapropazone may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidAzapropazone may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azapropazone.Vet Approved
CloranololAzapropazone may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Azapropazone is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Azapropazone.Experimental
CyclosporineAzapropazone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Azapropazone is combined with D-Limonene.Investigational
Dabigatran etexilateAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAzapropazone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAzapropazone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAzapropazone may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinAzapropazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Azapropazone.Experimental
DesirudinAzapropazone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azapropazone.Approved, Investigational
DextranAzapropazone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Azapropazone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Azapropazone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Azapropazone may increase the anticoagulant activities of Dextran 75.Approved
DibekacinAzapropazone may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone.Approved, Vet Approved
DicoumarolAzapropazone may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azapropazone.Approved
DihydrostreptomycinAzapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Azapropazone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azapropazone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azapropazone.Approved
DoxorubicinAzapropazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneAzapropazone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Azapropazone is combined with E-6201.Investigational
Edetic AcidAzapropazone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAzapropazone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone.Approved
EnoxacinAzapropazone may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAzapropazone may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Azapropazone.Experimental
EpanololAzapropazone may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole.Approved
EpirubicinAzapropazone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAzapropazone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.Approved
EquileninThe risk or severity of adverse effects can be increased when Azapropazone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin.Approved
EsmololAzapropazone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone sulfate.Approved
Etacrynic acidAzapropazone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Azapropazone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Azapropazone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Azapropazone is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Azapropazone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azapropazone.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Feprazone.Experimental
Ferulic acidAzapropazone may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Azapropazone.Approved, Investigational
FleroxacinAzapropazone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azapropazone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone.Approved
FluindioneAzapropazone may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAzapropazone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azapropazone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone.Approved, Nutraceutical, Vet Approved
FondaparinuxAzapropazone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAzapropazone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.Approved
FramycetinAzapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAzapropazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAzapropazone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAzapropazone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAzapropazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azapropazone.Approved, Withdrawn
GemifloxacinAzapropazone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAzapropazone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAzapropazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAzapropazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Azapropazone may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinAzapropazone may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Azapropazone is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Azapropazone is combined with HE3286.Investigational
HeparinAzapropazone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Higenamine.Investigational
HydralazineAzapropazone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.Approved, Investigational
Hygromycin BAzapropazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.Approved
IdarubicinAzapropazone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxAzapropazone may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Azapropazone.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.Approved
IndenololAzapropazone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen.Withdrawn
INNO-206Azapropazone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.Approved, Investigational
IsepamicinAzapropazone may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Azapropazone is combined with Istaroxime.Investigational
KanamycinAzapropazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.Approved
LabetalolAzapropazone may decrease the antihypertensive activities of Labetalol.Approved
LandiololAzapropazone may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azapropazone.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Azapropazone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Azapropazone.Approved, Investigational
LepirudinAzapropazone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAzapropazone may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololAzapropazone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAzapropazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Azapropazone.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Azapropazone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azapropazone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Azapropazone.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Azapropazone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Azapropazone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.Approved
MelagatranAzapropazone may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.Approved, Vet Approved
MepindololAzapropazone may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineAzapropazone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azapropazone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAzapropazone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.Approved
MetoprololAzapropazone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideAzapropazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinAzapropazone may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Azapropazone.Approved
NadololAzapropazone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAzapropazone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAzapropazone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone.Approved
Nalidixic AcidAzapropazone may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Azapropazone is combined with NCX 1022.Investigational
NeamineAzapropazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAzapropazone may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinAzapropazone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAzapropazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.Approved
NetilmicinAzapropazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nitroaspirin.Investigational
NorfloxacinAzapropazone may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.Approved
OlsalazineAzapropazone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azapropazone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Orgotein.Vet Approved
OtamixabanAzapropazone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.Approved
Oxolinic acidAzapropazone may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAzapropazone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib.Approved
ParomomycinAzapropazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Parthenolide.Investigational
PazufloxacinAzapropazone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAzapropazone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAzapropazone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAzapropazone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.Approved
PhenindioneAzapropazone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonAzapropazone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azapropazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.Approved, Investigational
PindololAzapropazone may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidAzapropazone may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinAzapropazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAzapropazone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.Approved, Investigational
Piromidic acidAzapropazone may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pirprofen.Experimental
Platelet Activating FactorAzapropazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAzapropazone may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAzapropazone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone.Approved
PractololAzapropazone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azapropazone.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Azapropazone can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol.Approved, Investigational
PropranololAzapropazone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azapropazone.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azapropazone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Azapropazone.Vet Approved
Protein CAzapropazone may increase the anticoagulant activities of Protein C.Approved
Protein S humanAzapropazone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAzapropazone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAzapropazone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone.Investigational
PuromycinAzapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.Approved, Experimental, Investigational
ReviparinAzapropazone may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAzapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.Approved, Investigational
RivaroxabanAzapropazone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Azapropazone.Investigational, Withdrawn
RosoxacinAzapropazone may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAzapropazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAzapropazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Azapropazone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azapropazone.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Azapropazone is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Azapropazone is combined with Serrapeptase.Investigational
SisomicinAzapropazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAzapropazone may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Azapropazone.Approved
SotalolAzapropazone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAzapropazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAzapropazone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinAzapropazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.Approved
SpironolactoneAzapropazone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone.Investigational
StreptomycinAzapropazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAzapropazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azapropazone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.Approved
SulodexideAzapropazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Azapropazone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Suxibuzone.Experimental
TacrolimusAzapropazone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Azapropazone.Approved
TalinololAzapropazone may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azapropazone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Azapropazone.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.Approved, Investigational
TemafloxacinAzapropazone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.Approved
TertatololAzapropazone may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAzapropazone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tixocortol.Approved
TobramycinAzapropazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.Approved
TorasemideAzapropazone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azapropazone.Approved
TranilastThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAzapropazone may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triptolide.Investigational
TrovafloxacinAzapropazone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAzapropazone may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azapropazone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Azapropazone.Investigational, Withdrawn
ValrubicinAzapropazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azapropazone.Approved
WarfarinAzapropazone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAzapropazone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azapropazone.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Azapropazone.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.Withdrawn
Zoptarelin doxorubicinAzapropazone may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAzapropazone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.

General References
Not Available
External Links
PubChem Compound
46937068
PubChem Substance
99443873
ChemSpider
25056860
ChEBI
38010
HET
AZQ
ATC Codes
M01AX04 — Azapropazone
PDB Entries
2bx8 / 2bxi / 2bxk

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)187Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
Predicted Properties
PropertyValueSource
Water Solubility0.641 mg/mLALOGPS
logP0.92ALOGPS
logP2.08ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)0.52ChemAxon
pKa (Strongest Basic)7.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity85.69 m3·mol-1ChemAxon
Polarizability31.94 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9389
Caco-2 permeable+0.5728
P-glycoprotein substrateNon-substrate0.5961
P-glycoprotein inhibitor IInhibitor0.8281
P-glycoprotein inhibitor IIInhibitor0.6484
Renal organic cation transporterNon-inhibitor0.7843
CYP450 2C9 substrateNon-substrate0.8218
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.6289
CYP450 1A2 substrateInhibitor0.5528
CYP450 2C9 inhibitorNon-inhibitor0.8735
CYP450 2D6 inhibitorNon-inhibitor0.9188
CYP450 2C19 inhibitorNon-inhibitor0.8614
CYP450 3A4 inhibitorNon-inhibitor0.8273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.725
Ames testAMES toxic0.5466
CarcinogenicityNon-carcinogens0.8321
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4784 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7311
hERG inhibition (predictor II)Non-inhibitor0.8171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazines
Sub Class
Aminotriazines
Direct Parent
Aminotriazines
Alternative Parents
Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
Amino-1,2,4-triazine / Aminotriazine / Pyrazolidinone / 1,3-dicarbonyl compound / Benzenoid / 1,2,4-triazine / Pyrazolidine / Carboxylic acid hydrazide / Guanidine / Azacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:21 / Updated on November 09, 2017 04:12